Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG monthly Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E30.61 EPS (ttm)3.10 Insider Own9.30% Shs Outstand2.52B Perf Week0.34%
Market Cap239.09B Forward P/E16.57 EPS next Y5.73 Insider Trans0.11% Shs Float2.12B Perf Month0.67%
Income7.21B PEG3.28 EPS next Q1.25 Inst Own10.70% Short Float0.15% Perf Quarter9.14%
Sales49.57B P/S4.82 EPS this Y66.90% Inst Trans-0.15% Short Ratio2.00 Perf Half Y1.71%
Book/sh23.12 P/B4.11 EPS next Y8.98% ROA9.20% Target Price101.00 Perf Year20.22%
Cash/sh3.46 P/C27.43 EPS next 5Y9.34% ROE20.50% 52W Range74.97 - 96.06 Perf YTD0.24%
Dividend2.83 P/FCF44.90 EPS past 5Y7.70% ROI11.50% 52W High-1.19% Beta0.65
Dividend %2.98% Quick Ratio0.70 Sales past 5Y0.20% Gross Margin70.90% 52W Low26.61% ATR0.76
Employees109000 Current Ratio0.90 Sales Q/Q9.90% Oper. Margin17.30% RSI (14)56.72 Volatility0.70% 0.68%
OptionableYes Debt/Eq0.57 EPS Q/Q10.50% Profit Margin23.80% Rel Volume1.37 Prev Close95.21
ShortableYes LT Debt/Eq0.42 EarningsJan 29 BMO Payout57.30% Avg Volume1.55M Price94.92
Recom1.50 SMA200.13% SMA502.23% SMA2007.11% Volume2,122,748 Change-0.30%
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Jan-23-20 10:42AM  Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 Zacks
08:51AM  Roche's Risdiplam Meets Primary Endpoint in Infants Study Zacks
08:13AM  Primary Drivers of the Chinese Economy Investopedia
Jan-21-20 06:21PM  Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe Zacks
09:26AM  Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth Zacks
08:41AM  Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe Zacks
Jan-20-20 09:45AM  Is Novartis AG (NVS) A Suitable Pick for Value Investors? Zacks
Jan-17-20 08:19AM  Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat? Zacks
08:11AM  Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates Zacks
Jan-15-20 11:00PM  Gene therapies test Europes willingness to pay Financial Times
Jan-13-20 01:04PM  Novartis to speed access to $10 billion heart drug via NHS deal Reuters
10:17AM  Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari Zacks
09:15AM  Novartis, U.K. National Health Service Partner for Trial of Cholesterol-Drug Candidate TheStreet.com
01:02AM  UKs NHS teams with Novartis to launch heart attack drug trial Financial Times
Jan-10-20 05:00PM  Regeneron's Phase II Candidate Promising in Primary Analysis Zacks
11:51AM  3 Biotech Stocks to Bank on for Buyouts in 2020 InvestorPlace
10:21AM  The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS Zacks
Jan-09-20 02:43PM  Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb Zacks
Jan-08-20 05:53PM  Among Top 5 Pharma Companies, Pfizer Was the Worst Performer in 2019 GuruFocus.com
07:00AM  Cambridge startup bringing AI to drug development raises $60M American City Business Journals
Jan-07-20 08:00AM  Is Biogen Stock A Buy On Renewed Hope In Alzheimer's Disease? Investor's Business Daily
07:26AM  Why Bank of America expects the hot European pharmaceuticals sector to stumble and its not a fear of U.S. drug prices MarketWatch
Jan-06-20 01:52PM  New antibiotics struggle to generate sales, pharma companies hurt Yahoo Finance Video
Jan-03-20 11:48AM  Novartis, Merck and Allergan join those raising U.S. drug prices for 2020 Reuters
10:01AM  Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study Zacks
09:19AM  Glaxo (GSK) Shares Continue to Witness Upside: Here's Why Zacks
Jan-02-20 04:42PM  Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta Zacks
11:53AM  Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward GuruFocus.com
Dec-31-19 08:45AM  3 Biotech Stocks Likely to Maintain Solid Momentum in 2020 Zacks
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-27-19 10:53AM  ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against Novartis AG NVS GlobeNewswire
Dec-26-19 11:53AM  Novartis AG (NVS) vs. Top 20 Hedge Fund Stocks in 2019 Insider Monkey
10:38AM  Epizyme (EPZM) Shares Soar on Lead Candidate's Progress Zacks
09:13AM  Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance Zacks
Dec-24-19 12:15PM  Biotech Leading in Q4: Best ETFs & Stocks Zacks
10:12AM  Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy Zacks
Dec-23-19 04:12PM  Pharma M&A Deals Likely To Be Smaller in 2020 GuruFocus.com
Dec-21-19 08:00AM  Biogen Announced a Big Stock Buyback. It May Not Be a Great Use of Cash. Barrons.com
Dec-20-19 09:22AM  Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs Zacks
06:03AM  Novartis wins Medicaid approval for new sickle cell drug in key U.S. states Reuters
Dec-19-19 05:51PM  4 More Biotechs With Blockbuster Potential GuruFocus.com
05:20PM  Fresh off first sickle cell drug approval, Global Blood strikes new deals American City Business Journals
10:01AM  AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU Zacks
07:52AM  The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
06:49AM  Novartis plans to give away world's costliest therapy to some patients Reuters
Dec-17-19 10:27AM  Novartis' Asthma Candidate Fails in LUSTER Phase III Studies Zacks
Dec-16-19 05:13PM  Why this company ponied up $99M for a mid-Peninsula building American City Business Journals
04:08PM  This Biotech Just Gave Up A Breakout Why An Analyst Is Still Bullish Investor's Business Daily
01:43PM  Amarins fish-oil pill now available to millions more patients. But its still no Lipitor MarketWatch
12:01PM  Regeneron Stock Is Downgraded. Analyst Cites Tough Competition From a Novartis Drug. Barrons.com
07:37AM  Novartis Gets Positive CHMP Opinion for Wet AMD Drug Beovu Zacks
Dec-15-19 07:06PM  Theres more upside for biotech even after 24% gains in two months MarketWatch
Dec-13-19 04:50PM  European Dividend Aristocrats: 41 Top-Flight International Dividend Stocks Kiplinger
02:42PM  FDA approves Sarepta's muscular dystrophy drug Yahoo Finance Video
12:19PM  Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020 Investor's Business Daily
10:29AM  Biotech Stocks Are Poised to Rise in 2020, Analyst Says. Here Is His Top Pick. Barrons.com
05:00AM  Paul Hudson seeks to write new prescription for Sanofi Financial Times
Dec-12-19 05:50PM  Novartis (NVS) Gains But Lags Market: What You Should Know Zacks
11:03AM  The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America Zacks
09:59AM  Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy Zacks
Dec-11-19 02:15PM  Top Research Reports for Novartis, AbbVie & Sanofi Zacks
08:54AM  Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA Zacks
07:21AM  The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga
07:00AM  Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting MarketWatch
Dec-10-19 04:16PM  Why Biotech ETFs are Surging to New Highs Zacks
04:00PM  Chinas Curing Cancer Faster and Cheaper Than Anywhere Else Bloomberg
08:55AM  Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research Zacks
12:26AM  StockBeat: Sanofi Surges After Ditching Diabetes, Cardio Research Investing.com
Dec-09-19 02:50PM  Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting PR Newswire
09:52AM  Gilead (GILD) Announces Positive Long-Term Data on Yescarta Zacks
Dec-06-19 11:58AM  Are more good times ahead for M&A? American City Business Journals
09:30AM  Biogen Up on New Data on Alzheimer's Candidate Aducanumab Zacks
09:21AM  Regeneron Reports Positive Data on Rare Blood Disorder Drug Zacks
07:39AM  The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga
07:36AM  Swiss approve insurance cover for Novartis, Gilead cell therapies Reuters
Dec-05-19 05:50PM  Novartis (NVS) Gains But Lags Market: What You Should Know Zacks
04:32PM  Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
04:18PM  U.S. FDA approves generic versions of Novartis blockbuster MS treatment Reuters
03:44PM  Companies Are Merging Like Mad. That Might Signal a Looming Economic Slowdown. Barrons.com
09:51AM  UPDATE 1-Novartis R&D boss says doesn't see big opportunity in oral SMA therapy Reuters
07:14AM  The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission Benzinga
Dec-04-19 08:04PM  Is Novartis AG (NVS) A Good Stock To Buy? Insider Monkey
05:52PM  Bayer and Teva Double Down on Worst M&A Deals of Decade GuruFocus.com
08:20AM  Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up Zacks
Dec-03-19 11:11AM  Astellas $3 billion gene therapy deal steadies investors after stalled Roche acquisition MarketWatch
09:29AM  Biogen's Shares Down on Rating Downgrade by Baird Analyst Zacks
09:26AM  Where to Buy Booming Biotech ETFs Investopedia
08:54AM  Gene-Therapy Firm Audentes Sold for Double Its Share Price. Analysts Expect More Deals. Barrons.com
08:26AM  Astellas bets $3 billion in gene therapy deal MarketWatch
Dec-02-19 09:04AM  Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space Zacks
06:33AM  Novartis-linked biotech firm raises $56M for new spinouts American City Business Journals
Nov-28-19 05:20AM  Novartis's $90 million Swiss factory to help solve cell therapy bottleneck Reuters
05:19AM  Novartis's $90 million Swiss factory to help solve cell therapy bottleneck Reuters
Nov-27-19 11:00PM  Novartis cholesterol deal highlights mass-market opportunity Financial Times
10:05AM  FOCUS-Pfizer, Novartis lead $2 bln spending spree on gene therapy production Reuters
07:14AM  Pfizer, Novartis lead $2 billion spending spree on gene therapy production Reuters
07:07AM  Pfizer, Novartis lead pharma spending spree on gene therapy production Reuters
03:28AM  Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD Zacks
Nov-26-19 07:06PM  Why Biotech ETFs Surged in Monday's Trading Session Zacks
04:15PM  This Biotech Broke Out Bullishly But Couldn't Hold Onto That Gain Investor's Business Daily
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; TRIO; Verily; and Pharming Group N.V. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerNov 12Buy12.00250,0003,000,0003,543,067Nov 12 04:15 PM
Novartis Bioventures Ltd10% OwnerMay 28Buy14.00168,6302,360,8201,769,641May 30 09:27 PM
Novartis Bioventures Ltd10% OwnerApr 26Sale1.03138,704142,8654,049,804Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 25Sale1.03563,096579,9894,188,508Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 24Sale1.0316,40316,8954,751,604Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 23Sale1.0327,55428,3814,768,007Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 22Sale0.977,1006,8874,795,561Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 15Sale0.9928,79428,5064,802,661Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 12Sale1.0430,90832,1444,831,455Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 11Sale1.0857,43862,0334,862,363Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 10Sale1.09140,230152,8514,919,801Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 09Sale1.0132,99133,3215,060,031Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 08Sale1.0227,52528,0765,093,022Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 05Sale1.0224,66125,1545,120,547Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 04Sale1.0147,90048,3795,145,208Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 03Sale0.9658,03355,7125,193,108Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 02Sale0.9751,75450,2015,251,141Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale1.9020,61039,1592,079,394Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale0.95116,909111,0645,302,895Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale1.85106,540197,0992,100,004Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale0.9163,10057,4215,419,804Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerMar 28Sale0.9488,83583,5055,482,904Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 27Sale0.9950,74950,2425,571,739Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 26Sale1.01177,762179,5405,622,488Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 15Sale1.9243,80084,0962,206,544Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 14Sale1.8813,80025,9442,250,344Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 13Sale2.12132,738281,4052,264,144Mar 15 05:25 PM